Earnings Feed
Start Free
BIO-TECHNE Corp·4

May 5, 4:12 PM ET

Crouse Steven C. 4

4 · BIO-TECHNE Corp · Filed May 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne (TECH) President Steven C. Crouse Converts 794 RSUs; 311 Withheld

What Happened

  • Steven C. Crouse, President — Diagnostic & Spatial Biology at Bio-Techne (TECH), had 794 restricted stock units (RSUs) convert into 794 common shares on May 1, 2026. Of those shares, 311 were withheld to satisfy tax withholding at $55.02 per share, generating proceeds of $17,111. The filing shows a separate derivative conversion entry (code M) recording the RSU-to-share conversion at $0 — this is a bookkeeping entry reflecting the derivative’s termination, not a sale of shares.

Key Details

  • Transaction date: 2026-05-01; filing date: 2026-05-05 (filed timely).
  • What occurred: Conversion/exercise of 794 RSUs into common stock (code M) and tax-withholding disposition of 311 shares (code F) at $55.02/share for $17,111.
  • Net shares delivered to insider: 794 vested − 311 withheld = 483 shares received.
  • Footnotes: F1 confirms each RSU = 1 share; F2 notes the 794 RSUs vest on 5/1/2026 (and again on 5/1/2027).
  • Shares owned after transaction: Not specified in the provided filing extract.

Context

  • This was a vesting/settlement of restricted stock units, not an open-market purchase or sale. The tax-withholding (F) entry is routine — shares are surrendered to cover withholding obligations. The derivative (M) entry at $0 simply records conversion/termination of the RSU award and should not be read as a market sale.

Insider Transaction Report

Form 4
Period: 2026-05-01
BIO-TECHNE CorpTECH
Crouse Steven C.
President - Diag & Spatial Bi
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-05-01+794→ 6,688 total
  • Tax Payment

    Common Stock

    2026-05-01$55.02/sh−311$17,111→ 6,337 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F2]
    2026-05-01−794→ 794 total
    → Common Stock (794 underlying)
Holdings

  • Restricted Stock Units

    [F1][F3]
    → Common Stock (1,800 underlying)
    1,800

  • Restricted Stock Units

    [F1][F4]
    → Common Stock (1,379 underlying)
    1,379

  • Restricted Stock Units

    [F1][F5]
    → Common Stock (3,737 underlying)
    3,737

  • Restricted Stock Units

    [F1][F6]
    → Common Stock (6,529 underlying)
    6,529

  • Stock Option (right to buy)

    [F7]
    Exercise: $97.13Exp: 2028-04-01→ Common Stock (3,856 underlying)
    3,856

  • Stock Option (right to buy)

    [F7]
    Exercise: $120.46Exp: 2028-08-06→ Common Stock (19,032 underlying)
    19,032

  • Stock Option (right to buy)

    [F8]
    Exercise: $94.52Exp: 2029-08-15→ Common Stock (24,560 underlying)
    24,560

  • Stock Option (right to buy)

    [F9]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (12,649 underlying)
    12,649

  • Stock Option (right to buy)

    [F10]
    Exercise: $73.46Exp: 2031-05-01→ Common Stock (7,327 underlying)
    7,327

  • Stock Option (right to buy)

    [F11]
    Exercise: $74.91Exp: 2034-08-15→ Common Stock (17,133 underlying)
    17,133

  • Stock Option (right to buy)

    [F12]
    Exercise: $48.61Exp: 2035-06-02→ Common Stock (5,434 underlying)
    5,434

  • Stock Option (right to buy)

    [F13]
    Exercise: $53.60Exp: 2035-08-15→ Common Stock (19,151 underlying)
    19,151

  • Performance Restricted Stock Units

    [F1][F14]
    → Common Stock (2,387 underlying)
    2,387

  • Restricted Stock Units

    [F1][F15]
    → Common Stock (735 underlying)
    735

  • Stock Option (right to buy)

    [F16]
    Exercise: $57.82Exp: 2036-03-02→ Common Stock (1,911 underlying)
    1,911
Footnotes (16)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F10]Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
  • [F11]Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
  • [F12]Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
  • [F13]Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
  • [F14]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F15]245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
  • [F16]Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
  • [F2]794 restricted stock units vest on 5/1/2026 and 5/1/2027.
  • [F3]600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
  • [F4]1,379 restricted stock units vest on 8/15/2026.
  • [F5]1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
  • [F6]2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
  • [F7]100% vested.
  • [F8]Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
  • [F9]Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed.|2026-05-05

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES